369638-69-7

Basic information

• Product Name: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester
• Synonyms: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester;5-（bormomethyl）pyrazin-2-ylcarbamate;tert-butyl N-[5-(Bromomethyl)pyrazin-2-yl]carbamate
• CAS NO: 369638-69-7
• Molecular Formula: C₁₀H₁₄BrN₃O₂
• Molecular Weight: 288.14
• Mol File: 369638-69-7.mol

Chemical Properties

• Boiling Point: 324.409 °C at 760 mmHg
• Flash Point: 149.997 °C
• Appearance: /
• Density: 1.482 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester(369638-69-7)
• EPA Substance Registry System: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester(369638-69-7)

Safety Data

• Hazardous Substances Data: 369638-69-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester is used as a building block in the development of new drug molecules due to its unique structure and pharmacological properties. Its potential applications include the creation of antimicrobial and pesticidal agents, contributing to the advancement of treatments for various diseases and pests.
Used in Organic Synthesis:
In the field of organic synthesis, (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester serves as a versatile intermediate for the synthesis of complex organic compounds. Its reactivity and stability facilitate the formation of a wide range of chemical products, expanding the scope of synthetic chemistry.
Used in Agrochemical Development:
(5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester is utilized in the development of agrochemicals, particularly as a component in the creation of new pesticides. Its antimicrobial and pesticidal properties make it a promising candidate for enhancing crop protection and managing pest infestations in agriculture.

InChI:InChI=1/C10H14BrN3O2/c1-10(2,3)16-9(15)14-8-6-12-7(4-11)5-13-8/h5-6H,4H2,1-3H3,(H,13,14,15)

Upstream product

• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 369638-68-6 tert-butyl (5-methylpyrazin-2-yl)carbamate 

Downstream Products

• 710322-47-7 tert-butyl 5-(cyanomethyl)pyrazin-2-ylcarbamate 
• 1610666-99-3 tert-butyl (5-(((4-cyanophenyl)(methyl)amino)methyl)pyrazin-2-yl)carbamate 
• 1610667-01-0 4-((imidazo[1,2-a]pyrazin-6-ylmethyl)(methyl)amino)benzonitrile 
• 1610667-00-9 4-(((5-aminopyrazin-2-yl)methyl)(methyl)amino)benzonitrile 
• 1610667-02-1 4-(((3-bromoimidazo[1,2-a]pyrazin-6-yl)methyl)(methyl)amino)benzonitrile 
• 1610669-52-7 4-[methyl({3-[4-(trifluoromethyl)phenyl]imidazo[1.2-a]pyrazin-6-yl}methyl)amino]benzonitrile 
• 1380646-54-7 acetic acid 5-[3-(3-fluorophenyl)-2-(4-methanesulfonylphenyl)-propionylamino]-pyrazin-2-ylmethyl ester 
• 1380646-32-1 (S)-3-(4-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380646-31-0 (R)-3-(4-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380646-25-2 acetic acid 5-[3-(4-fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-propionylamino]-pyrazin-2-ylmethyl ester 
• 1380646-02-5 3-(3-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380645-99-7 3-(4-Fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-N-(5-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-pyrazin-2-yl)-propionamide 
• 1380645-97-5 3-(4-Fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-N-(5-methoxymethyl-pyrazin-2-yl)-propionamide 
• 1360055-35-1 6-tert-butyl-2-{3-[5-(5-(cyclobutylaminomethyl)pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-2-(hydroxymethyl)phenyl}-8-fluoro-2H-phthalazin-1-one 

Relevant articles and documents

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Amido Compounds

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

TYPE II RAF KINASE INHIBITORS

The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

FLUORINATED HETEROARYLS

The present invention provides Formula (1A) XN O R 3 HN R 5 O R 4 R 2 R 1 (1A) 5 compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the glucokinase enzyme, where X, R 1, R 2, R 3, R 4, and R 5 are as described herein.

SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON

The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH 2 ; Y 1 , Y 2 , Y 3 , Y 4 and Y 5 , which may be identical or different, are each CH or N; however, at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N; Z 1 and Z 2 , which may be identical or different, are each CH or N; n is an integer from 1 to 3; R 1 is a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R 2 and R 3 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aromatic heterocyclic ring, or the like; and R 4 is a hydrogen atom, a lower alkyl group, a C 3 -C 6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.

Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9

5-Pyrimidinyl-2-aminothiazole 1 was identified as an inhibitor of cyclin-dependent kinases (CDKs) by a screening of the Merck sample repository. The introduction of a methyl group at the C-5 or C-6 position on the pyrimidine ring, directed toward the gate

Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists

The structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. The 2-halogen analogues showed enhanced antagonism compared to the prototype antagonist.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates

Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.